Ken Griffin Entera Bio Ltd. Transaction History

Citadel Advisors LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$0.64 - $1.72 $8,001 - $21,503	12,502 New	12,502 $20,000
Q3 2023 Nov 14, 2023	BUY	$0.6 - $0.88 $9,201 - $13,495	15,336 Added 47925.0%	15,368 $11,000
Q2 2023 Aug 14, 2023	BUY	$0.68 - $1.01 $21 - $32	32 New	32 $0
Q4 2022 Feb 14, 2023	BUY	$0.5 - $1.05 $15,232 - $31,988	30,465 New	30,465 $22,000
Q2 2022 Aug 15, 2022	SELL	$1.33 - $2.95 $3,192 - $7,080	-2,400 Reduced 15.94%	12,657 $17,000
Q1 2022 May 16, 2022	SELL	$1.91 - $3.23 $23,934 - $40,475	-12,531 Reduced 45.42%	15,057 $43,000
Q4 2021 Feb 14, 2022	SELL	$2.82 - $4.79 $34,601 - $58,773	-12,270 Reduced 30.78%	27,588 $77,000
Q3 2021 Nov 15, 2021	SELL	$4.43 - $6.29 $120,992 - $171,792	-27,312 Reduced 40.66%	39,858 $188,000
Q2 2021 Aug 16, 2021	BUY	$2.92 - $6.5 $196,136 - $436,605	67,170 New	67,170 $401,000
Q4 2020 Feb 16, 2021	SELL	$1.03 - $1.24 $22,680 - $27,304	-22,020 Closed	0 $0
Q3 2020 Nov 16, 2020	BUY	$1.05 - $2.2 $23,121 - $48,444	22,020 New	22,020 $28,000

5.31M

Ticker ENTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 28,809,900
Market Cap $57.9M
Description
Entera Bio Ltd., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of orally delivered large molecule therapeutics for unmet medical needs. The company's lead product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed ...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.